Background: Variability remains a challenge in lupus anticoagulant (LA) testing.
Objective: To validate LA test performance between Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core laboratories and examine agreement in LA status between Core and local/hospital laboratories contributing patients to this prospective registry.
Methods: Five Core laboratories used the same reagents, analyzer type, protocols, and characterized samples for LA validation. Non-anticoagulated registry samples were retested at the corresponding regional Core laboratories and anticoagulated samples at a single Core laboratory. Categorical agreement and discrepancies in LA status between Core and local/hospital laboratories were analyzed.
Results: Clotting times for the reference/characterized plasmas used for normalized ratios were similar between Core laboratories (CV <4%); precision and agreement for LA positive/negative plasma were similar (all CV ≤5%) in the four laboratories that completed both parts of the validation exercise; 418 registry samples underwent LA testing. Agreement for LA positive/negative status between Core and local/hospital laboratories was observed in 87% (115/132) non-anticoagulated and 77% (183/237) anticoagulated samples. However, 28.7% (120/418) of samples showed discordance between the Core and local/hospital laboratories or equivocal LA results. Some of the results of the local/hospital laboratories might have been unreliable in 24.7% (41/166) and 23% (58/252) of the total non-anticoagulated and anticoagulated samples, respectively. Equivocal results by the Core laboratory might have also contributed to discordance.
Conclusions: Laboratories can achieve good agreement in LA performance by use of the same reagents, analyzer type, and protocols. The standardized Core laboratory results underpin accurate interpretation of APS ACTION clinical data.
Keywords: Russell's viper venom time; antiphospholipid antibodies; antiphospholipid syndrome; lupus anticoagulant; thrombosis.
© 2019 International Society on Thrombosis and Haemostasis.
The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.Thromb Res. 2019 Mar;175:32-36. doi: 10.1016/j.thromres.2019.01.010. Epub 2019 Jan 18. Thromb Res. 2019. PMID: 30685523 Clinical Trial.
Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.J Thromb Haemost. 2015 Jul;13(7):1264-73. doi: 10.1111/jth.12917. Epub 2015 May 9. J Thromb Haemost. 2015. PMID: 25850997
Paired APTTs of low and high lupus anticoagulant sensitivity permit distinction from other abnormalities and achieve good lupus anticoagulant detection rates in conjunction with dRVVT.Int J Lab Hematol. 2019 Feb;41(1):60-68. doi: 10.1111/ijlh.12921. Epub 2018 Sep 24. Int J Lab Hematol. 2019. PMID: 30248243
Internal quality control and external quality assurance in testing for antiphospholipid antibodies: Part II--Lupus anticoagulant.Semin Thromb Hemost. 2012 Jun;38(4):404-11. doi: 10.1055/s-0032-1311993. Epub 2012 May 7. Semin Thromb Hemost. 2012. PMID: 22565408 Review.
AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update.Curr Rheumatol Rep. 2016 Oct;18(10):64. doi: 10.1007/s11926-016-0611-y. Curr Rheumatol Rep. 2016. PMID: 27646150 Review.
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
- Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem. 2007;53:1629-1635.
- Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7:1737-1740.
- Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012;157:47-58.
- CLSI Guideline. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A, 2014. 2014. Clinical and Laboratory Standards Institute, Wayne, PA, USA.